The clean energy sector shook off uncertainty to beat the broader market in 2025. Peter Krull, a director at Earth Equity Advisors, thinks the sector is set to keep rising in 2026. He gave his top five clean energy stocks to buy in the new year. Clean energy faced headwinds in 2025 as the White House prioritized fossil fuels, but the market showed remarkable resilience, which one investor thinks is set to boost renewable stocks further in 2026. After being buffeted by uncertainty related to energ ...

Stacks of gold coins forming an upward arrow beside a lab beaker and heart-rate icon. Key Points Stryker, Amgen, and Eli Lilly have all raised their dividends, signaling increased capital returns to shareholders despite varied stock performance in 2025. Amgen now offers an industry-leading 3.2% dividend yield, one of the few large-cap healthcare stocks with a yield above 3%. Wall Street maintains a positive outlook across all three names, with Stryker offering the highest implied upside at over 20%, fo ...

Core Viewpoint - COSCIENS Biopharma Inc. has approved a plan to voluntarily delist from Nasdaq while maintaining its listing on the Toronto Stock Exchange (TSX) to focus resources on core business needs and enhance operational efficiency [1][8]. Financial Highlights - For Q2 2025, total revenue was $2.7 million, a 17% increase compared to $2.3 million in Q2 2024 [17]. - Gross profit for Q2 2025 increased by 19% compared to the same period in 2024 [7]. - Operating expenses decreased by 28% compared to Q2 2024, totaling $3.3 million [18]. Strategic and Operational Updates - The company underwent a leadership change with a new CEO and a reconstituted Board of Directors, focusing on operational discipline and cost control [4][3]. - A zero-based budgeting initiative was launched, resulting in a 27% reduction in headcount to align costs with strategic priorities [6]. - The company is focusing on optimizing its revenue-generating base business and exploring new business development opportunities [5]. Nasdaq Delisting - The decision to delist from Nasdaq was driven by increasing costs associated with maintaining dual listings and a deteriorating cost-benefit ratio [8]. - The company plans to file a Form 25 with the SEC around August 25, 2025, with the delisting expected to be effective on or about September 5, 2025 [9][10]. Product and Market Development - The company is exploring new category expansion opportunities for its active ingredients, including beta glucan and avenanthramides [14]. - Despite challenges in the Macrilen product line, the company is assessing future development options and has ongoing clinical studies for its inflammation-related program [14]. Cash Position - As of June 30, 2025, the company had $9.3 million in cash and cash equivalents [15]. Overall Performance - For the six-month period ended June 30, 2025, the company reported a consolidated net loss of $6.0 million, compared to a loss of $2.8 million for the same period in 2024 [19]. - Total revenue for the six-month period was $4.2 million, a slight decrease from $4.4 million in the prior year [20].